SAB Biotherapeutics (SABSW) Equity Ratio (2020 - 2025)
Historic Equity Ratio for SAB Biotherapeutics (SABSW) over the last 6 years, with Q3 2025 value amounting to 0.9.
- SAB Biotherapeutics' Equity Ratio rose 3118.01% to 0.9 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.9, marking a year-over-year increase of 3118.01%. This contributed to the annual value of 0.59 for FY2024, which is 1391.8% down from last year.
- According to the latest figures from Q3 2025, SAB Biotherapeutics' Equity Ratio is 0.9, which was up 3118.01% from 0.4 recorded in Q2 2025.
- SAB Biotherapeutics' Equity Ratio's 5-year high stood at 0.9 during Q3 2025, with a 5-year trough of 0.3 in Q3 2021.
- For the 5-year period, SAB Biotherapeutics' Equity Ratio averaged around 0.57, with its median value being 0.58 (2022).
- In the last 5 years, SAB Biotherapeutics' Equity Ratio skyrocketed by 9441.02% in 2022 and then crashed by 4647.92% in 2025.
- SAB Biotherapeutics' Equity Ratio (Quarter) stood at 0.48 in 2021, then increased by 28.42% to 0.61 in 2022, then rose by 11.88% to 0.68 in 2023, then dropped by 13.92% to 0.59 in 2024, then skyrocketed by 53.14% to 0.9 in 2025.
- Its last three reported values are 0.9 in Q3 2025, 0.4 for Q2 2025, and 0.56 during Q1 2025.